Bank Of America: We're Still Buying Allergan


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


  • Allergan PLC (NYSE: AGN) shares are down 5 percent in the last three months, while shares of Pfizer Inc. (NYSE: PFE) have declined 8 percent over the same period.
  • BofA Merrill Lynch’s Sumant S. Kulkarni maintained a Buy rating on Allergen, with a price objective of $385.
  • Even if the deal with Pfizer does not come through, Allergen is poised to grow organically as well as strengthen its balance sheet, Kulkarni said.

According to media reports, Allergen and Pfizer are closer to a deal that would allow the latter company “to ‘invert’ for corporate tax purposes.” Meanwhile, the US Treasury is getting ready to issue new guidelines that could make inversions more tedious to pursue.

Analyst Sumant Kulkarni said that it was difficult to precisely predict how the Allergen-Pfizer combination, or All-zer, could play out as no deal had been agreed to as yet, and “extraneous pressure remain wildcards.”

Kulkarni pointed out two points related to Allergen, irrespective of whether or not the deal with Pfizer comes through:

  1. Allergen appears poised to grow organically, given its healthy product mix and robust pipeline, which includes more than 70 programs in development
  2. Allergen could pursue significant M&A sometime in the future, since the generics deals with Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA), expected to close in 1Q16), would strengthen the balance sheet by cash inflow of about $36 billion

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst ColorLong IdeasReiterationAnalyst RatingsTrading IdeasBofA Merrill LynchSumant S. Kulkarni